Literature DB >> 25209179

Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels.

Wan-Ju Xu1, Bao-Li Guo, Yu-Gang Han, Lei Shi, Wan-Shan Ma.   

Abstract

This study aimed to investigate the clinical values of serum alpha-fetoprotein-L3 (AFP-L3) and Golgi protein 73 (GP73) in the diagnosis of hepatocellular carcinoma (HCC) with low alpha-fetoprotein (AFP). From January 2011 to December 2013, 50 low-AFP HCC patients confirmed by the color Doppler flow imaging (CDFI) and pathological examinations were collected. Forty-five patients with chronic liver diseases were also selected, including 29 liver cirrhosis patients, 15 chronic hepatitis B patients, and one severe hepatitis patient. Furthermore, 100 health volunteers with no evidence of benign or malignant liver diseases were included. The enzyme-linked immunosorbent assay (ELISA) method was applied to the GP73 quantitative assay. Serum AFP concentrations were determined using immunoassays utilizing enhanced chemiluminescence. Diagnostic accuracy of GP73 and AFP-L3 assays for low-AFP HCC was evaluated using receiver operating characteristic (ROC) curve analysis. Statistical analyses were conducted with the GraphPad Prism 5.0 software. Low-AFP HCC patients (35/50) exhibited higher positive rates of AFP-L3 than non-HCC patients (5/45) and healthy controls (2/100) (both P < 0.05). There were also significant differences in the positive rate of GP73 of low-AFP HCC patients (40/50) compared to those of non-HCC patients (3/45) and healthy controls (1/100) (both P < 0.05). However, no obvious differences in the positive rates of AFP-L3 and GP73 were observed between non-HCC patients and healthy controls (both P > 0.05). ROC curves showed that the area under the curve (AUC) of AFP-L3 for the diagnosis of low-AFP HCC was 0.6994 (sensitivity [Sen] = 70.0 %, specificity [Spe] = 95.2 %, accuracy = 88.7 %), while the AUC of GP73 was 0.8411 (Sen = 80.0 %, Spe = 97.2 %, accuracy = 92.8 %). Compared with single detection, the combination of AFP-L3 and GP73 levels for the diagnosis of low-AFP HCC showed higher Sen (94.0 %), Spe (93.1 %), and better accuracy (93.3 %). Our findings provide empirical evidence that the combination of AFP-L3 and GP73 is a good diagnostic strategy for low-AFP HCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25209179     DOI: 10.1007/s13277-014-2506-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  43 in total

1.  International ethical guidelines for biomedical research involving human subjects.

Authors: 
Journal:  Bull Med Ethics       Date:  2002-10

2.  [The guidelines of prevention and treatment for chronic hepatitis B].

Authors: 
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2005-12

3.  AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.

Authors:  Kentaroh Yamamoto; Hiroshi Imamura; Yutaka Matsuyama; Yukio Kume; Hitoshi Ikeda; Gary L Norman; Zakera Shums; Taku Aoki; Kiyoshi Hasegawa; Yoshifumi Beck; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  J Gastroenterol       Date:  2010-07-13       Impact factor: 7.527

4.  Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.

Authors:  Hongyan Liang; Timothy M Block; Mengjun Wang; Bradley Nefsky; Ronald Long; Julie Hafner; Anand S Mehta; Jorge Marrero; Robert Gish; Pamela A Norton
Journal:  Cancer Biomark       Date:  2012       Impact factor: 4.388

5.  AFP-L3: a new generation of tumor marker for hepatocellular carcinoma.

Authors:  D Li; T Mallory; S Satomura
Journal:  Clin Chim Acta       Date:  2001-11       Impact factor: 3.786

Review 6.  Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis.

Authors:  Yuling Gan; Qiuzhen Liang; Xinghua Song
Journal:  Tumour Biol       Date:  2014-01-07

7.  Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.

Authors:  Jong Young Choi; Seung Won Jung; Hee Yeon Kim; Myungshin Kim; Yonggoo Kim; Dong Goo Kim; Eun-Jee Oh
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

8.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

9.  Mediterranean diet and hepatocellular carcinoma.

Authors:  Federica Turati; Dimitrios Trichopoulos; Jerry Polesel; Francesca Bravi; Marta Rossi; Renato Talamini; Silvia Franceschi; Maurizio Montella; Antonia Trichopoulou; Carlo La Vecchia; Pagona Lagiou
Journal:  J Hepatol       Date:  2013-11-14       Impact factor: 25.083

10.  Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases.

Authors:  Yanli Gu; Wenli Chen; Yu Zhao; Liyun Chen; Tao Peng
Journal:  Ann Clin Biochem       Date:  2008-11-13       Impact factor: 2.057

View more
  13 in total

1.  Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma.

Authors:  Lin Chen; Feihu Chu; Yali Cao; Jianguo Shao; Feng Wang
Journal:  Tumour Biol       Date:  2015-04-24

2.  Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma.

Authors:  Min Dong; Zhan-Hong Chen; Xing Li; Xiao-Yun Li; Jing-Yun Wen; Qu Lin; Xiao-Kun Ma; Li Wei; Jie Chen; Dan-Yun Ruan; Ze-Xiao Lin; Tian-Tian Wang; Dong-Hao Wu; Xiang-Yuan Wu
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

3.  The Value of Serum CHI3L1 for the Diagnosis of Chronic Liver Diseases.

Authors:  Hanyu Qiu; Xiaomei Zhang
Journal:  Int J Gen Med       Date:  2022-06-28

Review 4.  Biomarkers for the early diagnosis of hepatocellular carcinoma.

Authors:  Nobuhiro Tsuchiya; Yu Sawada; Itaru Endo; Keigo Saito; Yasushi Uemura; Tetsuya Nakatsura
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

5.  A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.

Authors:  Yigang Wang; Tao Liu; Panpan Huang; Hongfang Zhao; Rong Zhang; Buyun Ma; Kan Chen; Fang Huang; Xiumei Zhou; Caixia Cui; Xinyuan Liu
Journal:  Oncotarget       Date:  2015-05-30

Review 6.  Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Stijn Van Hees; Peter Michielsen; Thomas Vanwolleghem
Journal:  World J Gastroenterol       Date:  2016-10-07       Impact factor: 5.742

7.  A new use for an old index: preoperative high-density lipoprotein predicts recurrence in patients with hepatocellular carcinoma after curative resections.

Authors:  Lu Tian; Qian Yu; Xing-Hui Gao; Jiong Wu; Xiao-Lu Ma; Qian Dai; Chun-Yan Zhang; Yan Zhou; Yi-Chi Zhang; Bai-Shen Pan; Jian Zhou; Jia Fan; Xin-Rong Yang; Wei Guo
Journal:  Lipids Health Dis       Date:  2017-06-26       Impact factor: 3.876

Review 8.  Biomarkers for Hepatocellular Carcinoma.

Authors:  Jiatao Lou; LingFei Zhang; Shaogang Lv; Chenzi Zhang; Shuai Jiang
Journal:  Biomark Cancer       Date:  2017-02-28

9.  Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis.

Authors:  Wenli Sai; Li Wang; Wenjie Zheng; Junling Yang; Liuhong Pan; Yin Cai; Liwei Qiu; Haijian Zhang; Wei Wu; Dengfu Yao
Journal:  Hepat Mon       Date:  2015-12-29       Impact factor: 0.660

10.  Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma.

Authors:  Zhiguo Zhang; Yanying Zhang; Yeying Wang; Lingling Xu; Wanju Xu
Journal:  Onco Targets Ther       Date:  2015-12-31       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.